Visceral leishmaniasis: immunology and prospects for a vaccine

被引：78
|
作者：
Kaye, P. M. [1 ,2 ]
Aebischer, T. [3 ]
机构：
[1] Univ York, Ctr Immunol & Infect, Hull York Med Sch, York YO10 5YW, N Yorkshire, England
[2] Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England
[3] Robert Koch Inst, D-13353 Berlin, Germany
来源：
CLINICAL MICROBIOLOGY AND INFECTION | 2011年 / 17卷 / 10期
关键词：
Immunology; vaccine; visceral leishmaniasis; TRANSMISSION-BLOCKING VACCINE; T-CELLS; CUTANEOUS LEISHMANIASIS; DONOVANI INFECTION; MAJOR INFECTION; MEGLUMINE ANTIMONIATE; CANINE LEISHMANIASIS; ANTIGEN PRESENTATION; PROTECTIVE IMMUNITY; EXPRESSION CLONING;
D O I：
10.1111/j.1469-0691.2011.03610.x
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.
引用
收藏
页码：1462 / 1470
页数：9
相关论文
共 50 条
  • [31] Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis
    Breton, M
    Tremblay, MJ
    Ouellette, M
    Papadopoulou, B
    INFECTION AND IMMUNITY, 2005, 73 (10) : 6372 - 6382
  • [32] Immunoinformatics Approach to Design a Novel Subunit Vaccine Against Visceral Leishmaniasis
    Lari, Alireza
    Lari, Niloofar
    Biabangard, Atefeh
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2022, 28 (01)
  • [33] DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control
    Kumar, A.
    Samant, M.
    PARASITE IMMUNOLOGY, 2016, 38 (05) : 273 - 281
  • [34] Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine
    Santos, WR
    Aguiar, IA
    de Souza, EP
    de Lima, VMF
    Palatnik, M
    Palatnik-de-Sousa, CB
    VACCINE, 2003, 21 (32) : 4668 - 4676
  • [35] Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
    Borja-Cabrera, GP
    Mendes, AC
    de Souza, EP
    Okada, LYH
    Trivellato, FAD
    Kawasaki, JKA
    Costa, AC
    Reis, AB
    Genaro, O
    Batista, LMM
    Palatnik, M
    Palatnik-de-Sousa, CB
    VACCINE, 2004, 22 (17-18) : 2234 - 2243
  • [36] A gp63 based vaccine candidate against Visceral Leishmaniasis
    Sinha, Sukrat
    Sundaram, Shanthy
    Singh, Anand Prakash
    Tripathi, Ashutosh
    BIOINFORMATION, 2011, 5 (08) : 320 - 325
  • [37] Visceral Leishmaniasis
    Famularo, Giuseppe
    Mancini, Stefano
    MAYO CLINIC PROCEEDINGS, 2016, 91 (09) : 1322 - 1323
  • [38] Visceral leishmaniasis
    Mégarbane, B
    Bruneel, F
    Cazals-Hatem, D
    Adle-Biassette, H
    Houze, S
    Wolff, M
    Régnier, B
    REVUE DE MEDECINE INTERNE, 2001, 22 : 219S - 222S
  • [39] VISCERAL LEISHMANIASIS
    GARETT, A
    SOUTHWESTERN VETERINARIAN, 1978, 31 (02): : 125 - 128
  • [40] VISCERAL LEISHMANIASIS
    OZSOYLU, S
    HICSONMEZ, G
    ARCHIVES OF DISEASE IN CHILDHOOD, 1984, 59 (04) : 391 - 391
12345